- Home
- SRDX vs SAGE Comparison
SRDX vs SAGE Comparison
Compare SRDX & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRDX
- SAGE
- Stock Information
- Founded
- SRDX 1979
- SAGE 2010
- Country
- SRDX United States
- SAGE United States
- Employees
- SRDX N/A
- SAGE N/A
- Industry
- SRDX Medical/Dental Instruments
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- SRDX Health Care
- SAGE Health Care
- Exchange
- SRDX Nasdaq
- SAGE Nasdaq
- Market Cap
- SRDX 562.6M
- SAGE 462.2M
- IPO Year
- SRDX 1998
- SAGE 2014
- Fundamental
- Price
- SRDX $38.61
- SAGE $5.10
- Analyst Decision
- SRDX Hold
- SAGE Hold
- Analyst Count
- SRDX 4
- SAGE 20
- Target Price
- SRDX $43.00
- SAGE $12.89
- AVG Volume (30 Days)
- SRDX 219.6K
- SAGE 822.5K
- Earning Date
- SRDX 11-06-2024
- SAGE 10-29-2024
- Dividend Yield
- SRDX N/A
- SAGE N/A
- EPS Growth
- SRDX N/A
- SAGE N/A
- EPS
- SRDX N/A
- SAGE N/A
- Revenue
- SRDX $126,078,000.00
- SAGE $106,399,000.00
- Revenue This Year
- SRDX $13.75
- SAGE N/A
- Revenue Next Year
- SRDX $13.67
- SAGE $118.26
- P/E Ratio
- SRDX N/A
- SAGE N/A
- Revenue Growth
- SRDX N/A
- SAGE 837.60
- 52 Week Low
- SRDX $25.17
- SAGE $5.03
- 52 Week High
- SRDX $42.44
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- SRDX 50.28
- SAGE 28.88
- Support Level
- SRDX $37.86
- SAGE $5.86
- Resistance Level
- SRDX $38.93
- SAGE $5.87
- Average True Range (ATR)
- SRDX 0.40
- SAGE 0.51
- MACD
- SRDX 0.08
- SAGE -0.14
- Stochastic Oscillator
- SRDX 62.29
- SAGE 1.91
About SRDX Surmodics Inc.
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.